Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
dip should be .80 then its boom
im still on the fence on this one hope im not oo late, i probably buy the next dip?
i got in at .55, i think this will run some more tomorow. read the news carefully, its very juicy :)
BVTI double bottom off .78 on the intraday. power hour coming
any one real quick got in at .52 with news whats up
bought in on the news. $1 plus by day's end
is there a good fda approval board on IHUB?
little conso. after that will go uppppppp.....
come may this can be as much as $ 5 buck load up. it will fly when dndn is aproved for provenge. DNDN will be the first cancer vaccine approved by the FDA. So its only right that related companies ride the momentum as well. got my lil shares ready.
good luck.
here we gooooo i'm in.....
Chartbreaker1
WOW, great news. ABPIQ owns 81% of BVTI.
BVTI jumped almost 85% in last two trading sessions with good volume
BVTI in Pharma Voice Magazine - Research Report
http://www.box.net/shared/2t72oun7iy
BVTI - July 6,2009 - Therapeutic cancer vaccines show promise - Published in LA Times
They wouldn't prevent the disease, but might help people who are already fighting it.
By Jill U. Adams >>>
July 6, 2009
It's a deceptively simple idea: What if doctors could recruit the body's own immune system to fight cancer? The complexities of the immune system have kept this from becoming reality, until now. Three cancer vaccines -- for prostate cancer, melanoma and lymphoma -- have achieved positive results in so-called Phase 3 clinical trials -- the kind of studies that the Food and Drug Administration requires for a medicine to gain approval.
At the annual meeting of the American Society of Clinical Oncology held May 29 to June 2, researchers reported that a vaccine against follicular lymphoma, called BiovaxID, delayed remission after chemotherapy by more than one year, on average.
At the same meeting, other researchers said that a melanoma vaccine caused tumors to shrink in twice as many patients as those receiving a standard FDA-approved therapy.
And at the annual meeting of the American Urological Assn. in April, researchers reported that the vaccine Provenge extended the lives of men with metastatic prostate cancer by four months, on average.
Doctors are cautiously optimistic about the news. "Researchers have been working very hard to get some positive results," says Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society in Atlanta. "These three trials do suggest that vaccines will be used in the actual treatment of patients in the not too distant future."
But even with these tentative successes, a big question remains open: Will vaccines ever become more than small players in the medical treatment of cancer -- a group of diseases that presently kills some 560,000 Americans each year?
Only two cancer vaccines currently have FDA approval and both are strictly preventive, targeting viruses that can lead to cancer. Most U.S. children are vaccinated against hepatitis B, a virus that can cause liver disease and cancer. A vaccine for genital human papillomavirus (HPV), which can cause genital warts and cervical cancer, is now recommended for adolescent girls.
The new medicines -- called therapeutic cancer vaccines -- act differently. They are not preventive in the traditional concept of vaccines. Rather, patients already afflicted with cancer are vaccinated in the hope that the shots will tell their immune systems how better to fight growing tumors. And because the immune system has a long memory, it's hoped that this immune boost might also ward off cancer recurrences.
Researchers have been working on the strategy for at least four decades and have suffered many failures, even in vaccines that showed promise in Phase 1 and Phase 2 clinical trials, which test safety and effectiveness of experimental treatments in a small number of patients. "It's been a really frustrating journey for a lot of researchers," Lichtenfeld says. "A lot of hope and a lot of dashed hopes, unfortunately."
Basic research on the immune system in the last 10 to 15 years has led to an explosion of new knowledge about the intricacies of the immune system -- and some clues as to why these early strategies failed. For instance, it's now known that tumors can shut down immune activity in their vicinity. The three new vaccines, as well as many more under development, have incorporated past lessons and new knowledge to improve their odds.
Generally, vaccines are made from a substance that only cancer cells make (or that they make far more of than normal cells do) -- say, a protein that sits on the surface of a tumor cell. Then the vaccine is injected into the body. If the immune system senses that the substance is a foreign invader, then it starts to ramp up a response. The mechanisms vary, but essentially the body makes new immune cells and sends them out on search-and-destroy missions, seeking out anything that contains that same substance, or marker.
In the past, small protein fragments -- called antigens -- that are present in high amounts on cancer cells were used in cancer vaccines. But the ones that were chosen did not stimulate enough of an immune response to attack tumors effectively.
"We know a lot about tumor antigens," says Dr. Leisha Emens, an oncologist at Johns Hopkins University who is researching breast cancer vaccines. "I don't think we've done that great of a job identifying which ones are the most important."
You don't want just any immune response, you want one that will effectively attack the cancer cells, she says.
Dr. Donald Morton, chief of the melanoma program at the John Wayne Cancer Institute in Santa Monica, tells a cautionary tale. He led a different melanoma vaccineall the way through to a Phase 3 clinical trial. With 1,600 patients worldwide, it was much larger than the recent crop of studies. Morton says the rate of survival in the study was the highest he'd ever seen. However, that rate did not differ from the control group, who received only an immune stimulant, and the trial was halted in 2006. "There's no question that some patients responded to the vaccine," he says, based on a review of the data. However, many more patients did not.
The three vaccines with recent success don't work in all patients either, even though researchers tried to define patient populations that would be most amenable to vaccine therapy. In the melanoma vaccine trial, only patients with certain tissue types -- akin to tissue-typing for organ transplantation -- were included.
In the lymphoma vaccine trial, only patients who responded to chemotherapy and remained in remission for six months were eligible to receive the vaccine.
The vaccines don't measure up to other cancer therapies that have passed muster with the FDA in recent years, such as Herceptin, Gleevec and Rituxan, says Dr. John Glaspy, director of the Women's Cancers Program at UCLA's Jonsson Comprehensive Cancer Center. Gleevec, in particular, has revolutionized the care of the most common adult leukemia, known as chronic myeloid leukemia, raising five-year survival rates to 89% of patients taking the drug. Before Gleevec, patients' chances of surviving for five years with existing treatments were closer to 50%. "Those are huge breakthroughs in oncology that have made big impacts," Glaspy says.
Cancer vaccines have made comparable advances on the basic science front, but they have not yet translated into successful medicines. Yet researchers are reinvigorated by the recent successes because they suggest that, with combination therapies and careful patient selection, the vaccine strategy could work to fight cancer. "It's feasible," Glaspy says. "We're starting to see a few patients do well."
The ideal of therapeutic cancer vaccines still shimmers with promise: Imagine a medicine that's specific to a tumor and free of side effects. "If we can get the immune system to engage in this process, it works completely differently than any other cancer treatment out there. And the neat thing about the immune system is that it remembers," Emens says. "If we can get it to work, it has the potential to add a lot."
Even those stung with failure hold onto hope. "I remained convinced that the immune system is very important in the control of cancer," Morton says. "We just need to know what the right buttons are to push so that everybody responds."
health@latimes.com
http://www.latimes.com/features/health/la-he-cancervaccines6-2009jul06,0,6487100.story
Yes that was nice news here.
BVTI moving up nicely, consolidation in works
Biovest has already launched BiovaxID in Europe on named-patient basis last week and we are looking for some solid revenue numbers.
Charts added to IBOX !
BVTI Revenue Projection
http://sec.gov/Archives/edgar/data/704384/000119312506152662/dex991.htm
Move to Slide # 10 for details
Biovest launches BiovaxID in Europe on named-patient
http://www.tradingmarkets.com/.site/news/Stock%20News/2396852/
Great NEWS ----> This will move quite nicely.
Biovest launches BiovaxID in Europe on named-patient
http://www.tradingmarkets.com/.site/news/Stock%20News/2396852/
Expected more volume activity today from the news this morning.
Took a starter position here with 30k shares at $0.46 per share avg.
Quite bullish with that news this morning. Chart is looking awfully nice as well.
BVTI up 29% today
More UPDATES expected real soon here with BVTI.
Thanks for all the info...
"BVTI plan to make BiovaxID available throughout most of Europe on a named-patient basis. This compassionate-use drug access program allows European physicians to prescribe drugs to qualifying patients before approvals are granted, assuming the protocols for each participating country are followed."
Float is real thin here.
Nice, just looked at the PPT presentation, so 56% is held by accentia ? Wonder how thin the float might be if you say many are in strong hands...
Do you have more info about that ?
YES, many are long term investors, so they are not concerned about the current price. Although, BVTI is doing much behind the scene, another major pharma partner in USA or takeover is in works.
Just went through filings quick..can it be that people bought shares at much higher prices ?
SALE in EUROPE started, partnered with IDIS Pharma. Big step for BVTI moving forward.
Ok got me some...
BVTI: Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis ((((LINK BACK FOR DD))))
Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis Biovest and idis Partner to Facilitate Patient Access to Lymphoma Vaccine
TAMPA, Fla., Jun 28, 2009 (BUSINESS WIRE) -- --Phase III Study Results to Be Presented at "Best of ASCO" in Paris
Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID(R), Biovest's personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin's lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.
According to world-renowned hematologist and lymphoma research pioneer, Professor Volker Diehl, M.D., Ph.D., Professor of Medicine, University of Cologne, "With the availability of this truly patient-specific vaccine, I believe hematologists now have a new, safe lymphoma treatment option capable of enhancing xisting chemotherapeutic and monoclonal antibody treatment options by training the patient's own immune system to selectively recognize and attack cancer cells, resulting in potentially longer lasting remissions. As follicular lymphoma so far is supposed to be a generally incurable and fatal blood cancer, it is with great hope and expectations that I welcome such a highly personalized therapeutic approach in addressing an urgent unmet need." Prof. Dr. Diehl founded the German Hodgkin Study Group and is a recipient of the Bundesverdienstkreuz (Order of Merit of the Federal Republic of Germany), awarded by the German government for his lifetime achievements in the field of lymphoma research.
The BiovaxID Phase III study results were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, reporting that an eight year pivotal, randomized, multi-center, double-blind, controlled clinical study demonstrated that BiovaxID significantly prolonged disease-free
survival in follicular non-Hodgkin's lymphoma. The study found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine - an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first vaccine targeting lymphoma ever to demonstrate such a disease-free survival benefit and because the
vaccine is comprised of the patient's own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.
Later today, the BiovaxID Phase III study results will again be presented at the "Best of ASCO" event to be held at the Maison de la Chimie, in Paris, France at 4:15 p.m. local time. The iscussants for the BiovaxID abstract (abstract 33572) will be Jean-Luc Harousseau, M.D., Head of the Department of Clinical Hematology at the Central Laboratory of Hematology in Nantes, France and Vice President of the French Society of Hematology, and Christian Gisselbrecht, M.D., Ph.D., of the Institut d'Hematologie, Hopital Saint-Louis in Paris, France.
Prof. Dr. Diehl also anticipates that the addition of BiovaxID booster shots could substantially bolster patient results, stating, "The recently reported Phase III results, while impressive, did not include a BiovaxID maintenance regimen consisting of periodic booster shots. Such a maintenance booster regimen may be key in continuing to stimulate a robust and enduring immune response, thus further improving results, and perhaps even resulting in durable remissions for some patients." Biovest intends to include multiple booster vaccines for potential maintenance therapy purposes as part of the vaccine delivery for prescriptions processed under the named-patient program.
As BiovaxID is individually manufactured from a tissue biopsy obtained from a patient's own tumor, a patient wishing to participate in the named-patient program must undergo a lymph node biopsy prior to receiving chemotherapy/monoclonal antibody therapy. Those cells collected by biopsy will then undergo a preparation process performed by Biovest with the resulting
vaccine material then preserved until manufacture of the final vaccine is prescribed by the patient's physician through idis. The vaccine is typically administered approximately 6 months following the end of chemotherapy, and consists of five BiovaxID vaccinations, subcutaneously injected, over a 6 month
period (months 1,2,3,4 and 6). As an adjuvant therapy, at each vaccination cycle, patients will also receive four daily injections of an immune stimulating agent, GM-CSF. At the physician's option, a periodic vaccine booster maintenance regimen may also be prescribed.
A named-patient program is a compassionate-use drug supply program under which physicians are permitted to supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs may be administered to
patients who are suffering from a serious illness prior to the drug being approved by the European Medicines Evaluation Agency (EMEA). "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient, assuming compliance with the local regulatory protocols respective to each participating
country. In Europe, under the named-patient program, the drug is most often purchased through the national health system.
Contact Information for BiovaxID Named-Patient Program:
Licensed hematologists can learn more regarding BiovaxID and the named-patient program by contacting:
idis Limited (United Kingdom)
Telephone: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: internationalsales@idispharma.com
About BiovaxID(R)
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers
B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells develop and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on
the cell's surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype
obtained from a sample of the patient's tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient's T-cells (immune cells that kill cancerous cells) to seek out and destroy only the
diseased B-cells. BiovaxID is the only hybridoma (patient's lymphoma cells are fused to a heteromyeloma cell line to produce the tumor specific idiotype protein) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune
response against the cancer, as well as "training" the immune system to maintain continuous response if cancerous cells were to return.
About idis Limited
idis is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. idis supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. For more information on idis please visit their website at http://www.idispharma.com.
About Biovest International, Inc.
Biovest International, Inc. (Other OTC: BVTI) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned (75%) subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ) with its remaining shares publicly
traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of
cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID(R), which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
GREAT NEW$ BVTI. This will be pay off real BIG.
Personalized Anti-Cancer Vaccine, BiovaxID(R), Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis
Jun 28, 2009 08:00:01 (ET)
TAMPA, Fla., Jun 28, 2009 (BUSINESS WIRE) -- --Phase III Study Results to Be Presented at "Best of ASCO" in Paris
Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID(R), Biovest's personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin's lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.
According to world-renowned hematologist and lymphoma research pioneer, Professor Volker Diehl, M.D., Ph.D., Professor of Medicine, University of Cologne, "With the availability of this truly patient-specific vaccine, I believe hematologists now have a new, safe lymphoma treatment option capable of enhancing existing chemotherapeutic and monoclonal antibody treatment options by training the patient's own immune system to selectively recognize and attack cancer cells, resulting in potentially longer lasting remissions. As follicular lymphoma so far is supposed to be a generally incurable and fatal blood cancer, it is with great hope and expectations that I welcome such a highly personalized therapeutic approach in addressing an urgent unmet need." Prof. Dr. Diehl founded the German Hodgkin Study Group and is a recipient of the Bundesverdienstkreuz (Order of Merit of the Federal Republic of Germany), awarded by the German government for his lifetime achievements in the field of lymphoma research.
The BiovaxID Phase III study results were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, reporting that an eight year pivotal, randomized, multi-center, double-blind, controlled clinical study demonstrated that BiovaxID significantly prolonged disease-free survival in follicular non-Hodgkin's lymphoma. The study found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine - an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first vaccine targeting lymphoma ever to demonstrate such a disease-free survival benefit and because the vaccine is comprised of the patient's own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.
Later today, the BiovaxID Phase III study results will again be presented at the "Best of ASCO" event to be held at the Maison de la Chimie, in Paris, France at 4:15 p.m. local time. The discussants for the BiovaxID abstract (abstract 33572) will be Jean-Luc Harousseau, M.D., Head of the Department of Clinical Hematology at the Central Laboratory of Hematology in Nantes, France and Vice President of the French Society of Hematology, and Christian Gisselbrecht, M.D., Ph.D., of the Institut d'Hematologie, Hopital Saint-Louis in Paris, France.
Prof. Dr. Diehl also anticipates that the addition of BiovaxID booster shots could substantially bolster patient results, stating, "The recently reported Phase III results, while impressive, did not include a BiovaxID maintenance regimen consisting of periodic booster shots. Such a maintenance booster regimen may be key in continuing to stimulate a robust and enduring immune response, thus further improving results, and perhaps even resulting in durable remissions for some patients." Biovest intends to include multiple booster vaccines for potential maintenance therapy purposes as part of the vaccine delivery for prescriptions processed under the named-patient program.
As BiovaxID is individually manufactured from a tissue biopsy obtained from a patient's own tumor, a patient wishing to participate in the named-patient program must undergo a lymph node biopsy prior to receiving chemotherapy/monoclonal antibody therapy. Those cells collected by biopsy will then undergo a preparation process performed by Biovest with the resulting vaccine material then preserved until manufacture of the final vaccine is prescribed by the patient's physician through idis. The vaccine is typically administered approximately 6 months following the end of chemotherapy, and consists of five BiovaxID vaccinations, subcutaneously injected, over a 6 month period (months 1,2,3,4 and 6). As an adjuvant therapy, at each vaccination cycle, patients will also receive four daily injections of an immune stimulating agent, GM-CSF. At the physician's option, a periodic vaccine booster maintenance regimen may also be prescribed.
A named-patient program is a compassionate-use drug supply program under which physicians are permitted to supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs may be administered to patients who are suffering from a serious illness prior to the drug being approved by the European Medicines Evaluation Agency (EMEA). "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient, assuming compliance with the local regulatory protocols respective to each participating country. In Europe, under the named-patient program, the drug is most often purchased through the national health system.
Contact Information for BiovaxID Named-Patient Program:
Licensed hematologists can learn more regarding BiovaxID and the named-patient program by contacting:
idis Limited (United Kingdom)
Telephone: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: internationalsales@idispharma.com
About BiovaxID(R)
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers
B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells develop and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on the cell's surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype obtained from a sample of the patient's tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient's T-cells (immune cells that kill cancerous cells) to seek out and destroy only the diseased B-cells. BiovaxID is the only hybridoma (patient's lymphoma cells are fused to a heteromyeloma cell line to produce the tumor specific idiotype protein) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune response against the cancer, as well as "training" the immune system to maintain continuous response if cancerous cells were to return.
About idis Limited
idis is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. idis supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. For more information on idis please visit their website at http://www.idispharma.com .
About Biovest International, Inc.
Biovest International, Inc. (Other OTC: BVTI) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned (75%) subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID(R), which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
For further information, please visit: http://www.biovest.com
Forward-Looking Statements:
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID(R), AutovaxID(TM), events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
SOURCE: Biovest International, Inc.
Biovest International, Inc.
Corporate Contact:
Douglas Calder, Director of Investor Relations & Public Relations
813-864-2554, ext.258
dwcalder@biovest.com
BVTI Moving up. Partnership and sales deal in EUROPE moving forward. Expecting an update from co soon. Link Back for DD.
ASCO- 2009 Updates- BVTI in Focus
Therapeutic Vaccine Delays Lymphoma Recurrence
While follicular lymphoma frequently responds to chemotherapy and can have a long course, the disease is considered incurable because it almost always recurs. Researchers of a lymphoma trial hope that BiovaxID, a personalized vaccine, could help delay those recurrences.
The study included 117 patients who experienced at least a six-month remission after chemotherapy, and retained that remission until receiving either BiovaxID or a control vaccine. Each patient randomized to the BiovaxID arm was given a series of injections of a vaccine developed from their own cancer cells, making it a specialized targeted drug against the individual’s malignant B cells. After a median of nearly five years follow-up, BiovaxID improved cancer-free survival by 47 percent, delaying recurrence for more than a year, from 30.6 months to 44.2 months, when compared with the control vaccine. No major differences in side effects occurred between the two arms.
Researchers stressed the need for future studies, including combining the vaccine with targeted drugs such as Rituxan (rituximab), an agent that is now a standard of care for lymphoma.
http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/1152
BVTI - Consolidated DD
1. Special Report( BVTI): Customized Cancer Vaccines Finally (Maybe) Arrive- Jun 12 2009, 12:00 AM EST
http://www.genengnews.com/news/bnitem.aspx?name=56088213
2. BVTI - BiovaxID sale in EU (Named Patient Program)
(Courtesy , Poster on Yahoo Message Board)
IDIS Pharma in EUROPE (http://www.idispharma.com/showcontent.asp?CollectionID=@0000000004) has started the sale
of BiovaxID in EU on compassionate use basis. If you know anyone with NHL, please forward them contact info
below.
Good luck to all,
=======================================
Dear XXX,
Thank you for your e-mail and I can confirm that IDIS has started the BiovaxID Named Patient Program, Please request that your physician contacts our Global Sales Team at IDIS, using the contact details below, if further information is required as IDIS is only permitted to deal with qualified and verified medics and medical facilities:
E-mail - globalsales@idispharma.com
Tel + 44 1932 824100
Fax + 44 1932 824300
Kind Regards
Colleen
3. BVTI: Presentation from European Society for Medical Oncology (ESMO)
http://www.esmo.org/fileadmin/media/presentations/826/LCT10001552.ppt
4. BVTI- PPT filed with the SEC- An important read
http://sec.gov/Archives/edgar/data/704384/000119312506152662/dex991.htm
Move to Slide # 10:
5.In addressing regulatory and commercial plans for BiovaxID, Biovest's President and General Counsel, Samuel Duffey, commented, "We have already initiated discussions with the FDA and EMEA and are preparing for further meetings with those agencies and other international regulatory authorities in order to share our significant results and determine the most appropriate approval regulatory pathways. In addition, we plan to make BiovaxID available throughout most of Europe on a named-patient basis. This compassionate-use drug access program allows European physicians to prescribe drugs to qualifying patients before approvals are granted, assuming the protocols for each participating country are followed."
6. Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID(R),Presented at ASCO Plenary Session
Ref: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38300750
7. BVTI- Media BUZZ
7.a. Story from ABC NEWS
http://www.abcnews.go.com/Health/CancerPreventionAndTreatment/story?id=7718919&page=1
7.b. Video from NBC NEWS
http://www.msnbc.msn.com/id/21134540/vp/31030637#31030637
7.c. Article from NY Times
http://www.nytimes.com/2009/06/01/business/01drug.html?ref=business
7.d. Article from Houston Chronicle
http://www.chron.com/disp/story.mpl/front/6451203.html
From BiomedReports
http://biomedreports.com/articles/most-popular/1099-pink-bio-play-may-move-markets-with-cancer-vaccine.html
8. BVTI: These are impressive results and may indicate that BiovaxID will be one of the first vaccines approved by the U.S. Food and Drug Administration.
Ref: http://professional.cancerconsultants.com/oncology_main_news.aspx?id=43607
I bought another 1500 shares today.....BVTI looks like it is ready to rebound!
I think BVTI is ready to make another run sometime soon....it looks like it has finally hit the bottom!
BVTI should make another run for it. Picked up a few shares today. We gotta get this board back to life
I bought some shares today....I think BVTI will make another run.....
I've never seen people trying to sell on news so fast before in my life.....Got my 10000 sold at 1.30!!!! missed the 1.45-50 action....weeeeeeeeeeeeeeeeee
Huge move coming today. Big news followed by a big move!!
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
320
|
Created
|
01/27/06
|
Type
|
Free
|
Moderators |
http://www.biovest.com
Biovest International Inc, is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically-integrated specialty biopharmaceutical company with services to commercialize targeted therapeutics. Accentia is a publicly traded company (NASDAQ: ABPI) that has a product portfolio featuring targeted therapeutics, specialty sales and marketing, pharmacoeconomic services, product development, and specialty distribution.
Biovest has a deep foundation in the manufacture of biological drugs from small research scale quantities to large volumes for Phase I and Phase II clinical material. In addition, Biovest International develops, manufactures, and markets patented cell culture systems and equipment to pharmaceutical, diagnostic and biotechnology companies, as well as leading research institutions worldwide. For over 10 years the company has operated the National Cell Culture Center (NCCC) under a grant from the National Institutes of Health.
Biovest is the holder of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute for the commercialization of BiovaxID, a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin's lymphoma. This therapy, referred to as BiovaxID, is currently in a phase 3 pivotal trial at 24 major medical institutions in the US.
SEC FILINGS
http://phx.corporate-ir.net/phoenix.zhtml?c=154286&p=irol-sec
RECENT NEWS
http://finance.yahoo.com/q?s=BVTI.OB
DAILY CHART
WEEKLY CHART
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |